Microvascular Tissues

Microvascular Tissues is a commercial-stage biotech company that has developed mVASC®, a unique extracellular matrix product derived from human cadaveric microvascular tissues. The product is designed as an off-the-shelf graft for repairing complex skin wounds that extend into the hypodermis, aiming to leverage the inherent structural and biological properties of native ECM to promote healing. Spun out from Tornier, Inc. (now Stryker) in 2014/2015, the company is privately held and has advanced its lead product to market. Its strategy focuses on addressing vascular deficiencies in wound care, a niche with significant unmet need in chronic and surgical wounds.

Proprietary processing of human cadaver-derived hypodermal extracellular matrix (ECM) containing native microvascular architecture (arterioles, capillaries, venules). The platform involves aseptic harvest, lyophilization, and terminal sterilization to create an off-the-shelf, bioactive scaffold intended to promote angiogenesis and tissue repair.

mVASC competes in the bioactive wound matrix segment against products like Organogenesis's Apligraf®/Dermagraft®, Integra's Omnigraft®, and various porcine/xenogeneic ECM products. Its differentiation is the specific sourcing from microvascular tissues, but it faces competitors with greater sales resources, clinical data, and brand recognition. Success requires clearly communicating its unique angiogenic potential to clinicians.